Sanofi’s vaccines global business unit Sanofi Pasteur and Translate Bio have reported preclinical trial results that showed mRNA-based vaccine candidate, MRT5500 induced a favourable immune response against SARS-CoV-2.
These results support progressing the vaccine candidate into clinical development, with a Phase I / II trial expected to commence in the fourth quarter of this year.
Go deeper with GlobalData
Sanofi Pasteur and Translate Bio are developing MRT5500 as part of a partnership deal.
Four dose levels of the vaccine candidate were evaluated at 0.2µg, 1µg, 5µg and 10µg in mice using a two-dose schedule administered three weeks apart.
In non-human primates (NHPs), three dose levels of 15µg, 45µg and 135µg MRT5500 were analysed with a similar two-dose approach.
Data showed that the vaccine candidate induced dose-dependent levels of binding antibodies and neutralising antibodies specific to SARS-CoV-2 spike protein significantly higher than those observed in patients with Covid-19.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMoreover, MRT5500-immunised mice and NHPs demonstrated a Th1-biased T-cell response against SARS-CoV-2.
Translate Bio CEO Ronald Renaud said: “The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favourable immune response in both mice and non-human primates.
“Importantly, these results provide additional support for using our mRNA platform to potentially expedite the development of alternative approaches to traditional vaccines.”
In 2018, the companies signed a collaboration and exclusive license agreement to develop mRNA vaccines for up to five infectious disease pathogens.
Initially, the deal expanded in March to include the development of a novel mRNA vaccine for Covid-19.
Sanofi Pasteur executive vice-president and global head Thomas Triomphe said: “Today’s presentation of these positive results is another development milestone for providing a safe and effective potential vaccine against SARS-CoV2 and shows how promising this technology is.”
In September, Sanofi and GlaxoSmithKline (GSK) initiated a Phase I / II trial to evaluate their adjuvanted recombinant protein-based vaccine candidate against Covid-19.
